Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 41.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,455 shares of the pharmaceutical company’s stock after purchasing an additional 1,876 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Vertex Pharmaceuticals were worth $983,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in VRTX. Old Mutual Global Investors UK Ltd. lifted its position in Vertex Pharmaceuticals by 1,384.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after purchasing an additional 1,114,939 shares during the last quarter. Jennison Associates LLC lifted its position in Vertex Pharmaceuticals by 19.0% during the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after purchasing an additional 962,644 shares during the last quarter. Point72 Asset Management L.P. lifted its position in Vertex Pharmaceuticals by 8,061.1% during the third quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after purchasing an additional 898,089 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Vertex Pharmaceuticals by 9,422.3% during the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares during the last quarter. Finally, AJO LP bought a new stake in Vertex Pharmaceuticals during the second quarter valued at approximately $71,956,000. Institutional investors and hedge funds own 93.09% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $145.12 on Thursday. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The company has a market cap of $36,782.18, a price-to-earnings ratio of 242.40, a P/E/G ratio of 3.48 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same period in the previous year, the firm earned $0.16 earnings per share. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. DA Davidson assumed coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. BTIG Research assumed coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price objective for the company in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $173.22.

In related news, CEO Jeffrey M. Leiden sold 125,000 shares of Vertex Pharmaceuticals stock in a transaction on Monday, December 11th. The shares were sold at an average price of $141.35, for a total value of $17,668,750.00. Following the transaction, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 343,519 shares of company stock worth $49,488,660. 1.80% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Ladenburg Thalmann Financial Services Inc.” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/21/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-ladenburg-thalmann-financial-services-inc.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.